Search
Search Results
-
„Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?
Obesity is a chronic disease with a high and still increasing prevalence and many comorbidities, making it a growing global problem. Achieving...
-
Sindrome dell’ovaio policistico: ruolo del glucagon-like peptide 1 (GLP-1) nella regolazione dell’asse ipotalamo-ipofisi-ovaio
Obesity and insulin resistance associated to Polycystic Ovary Syndrome (PCOS) prompted the development of clinical studies evaluating the...
-
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy
Aims/hypothesisDiabetic peripheral neuropathy (DPN) is a highly prevalent cause of physical disability. Glucagon-like peptide-1 receptor agonists...
-
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic liver disease closely associated with the epidemics of obesity and type 2 diabetes...
-
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Purpose of ReviewThe glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) liraglutide and semaglutide, and the dual GLP-1/glucose-dependent...
-
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by excess cardiovascular risk. Glucagon-like peptide 1 (GLP1)...
-
Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities
BackgroundGlucagon-like peptide-1 (GLP-1) analogs are approved for the treatment of obesity in adults and adolescents. Reports have emerged that the...
-
Pregnancy glucagon-like peptide 1 predicts insulin but not glucose concentrations
AimsIncretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP) cause increased insulin secretion in non-pregnant adults,...
-
Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus
IntroductionPharmacogenetics studies suggest that genetic variants have a possible influence on the inter-individual differences in therapeutic...
-
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
BackgroundGlucagon-like peptide 1 receptor agonists (GLP1RAs) are used in the treatment of diabetes and obesity. Their slowing effect of gastric...
-
The role of the HERG channel in the secretion of glucagon-like peptide-1 (GLP-1) from murine intestinal L-cells
The HERG ion channel belongs to the voltage-gated potassium (Kv) channel family and is involved in potassium efflux during cellular repolarization....
-
Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
BackgroundPatients with type 2 diabetes (T2D) tend to have nonalcoholic fatty liver disease (NAFLD) with poorer prognosis. We performed this research...
-
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis
BackgroundA significant number of patients face the issue of weight gain (WG) or inadequate weight loss (IWL) post-bariatric surgery for obesity....
-
Idiopathic Intracranial Hypertension After Abrupt Cessation of Medication: A Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Cessation and Review of the Literature
Purpose of ReviewThe purpose of this review is two-fold: (1) to discuss a case report of idiopathic intracranial hypertension (IIH) after abrupt...
-
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
BackgroundThe ability of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to decrease certain microvascular events has called for the...
-
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in...
-
Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are...
-
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Asthma is a chronic inflammatory disease involving multiple mediators and cytokines. While our current treatments have shown significant therapeutic...
-
Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice
Aggression is a complex social behavior, which is provoked in the defense of limited resources including food and mates. Recent advances show that...
-
Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study
BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular benefits in type 2 diabetes, but none of the cardiovascular trials...
